A randomised, multi-factorial, adaptive platform clinical trial. The Trial will simultaneously investigate the best option in multiple areas of practice for COVID-19 patients admitted to hospital but not so unwell that they need intensive care. Patients will be randomly allocated to one of the treatment options in each of the areas of practice.
Mega-ROX is a series of multi-centre, multinational, randomised, parallel-group, registry-embedded clinical trials nested within an overall 40,000-patient trial sample. The trial will compare conservative vs. liberal oxygenation targets.
A 8,000 patient, multi-centre, randomised controlled trial to compare the safety and efficacy of Plasma-Lyte 148® in comparison with saline .
A multi-centre, phase II, randomised, open label, clinical trial comparing combined prophylactic intravenous paracetamol and early targeted physical cooling for fever with standard temperature management in mechanically ventilated adults without acute brain pathologies who are expected to be ventilated beyond the day after randomisation.
A randomised, embedded, multi-factorial, adaptive platform clinical trial. The Trial will simultaneously investigate the best of two or three options in 4 areas of practice for patients admitted to intensive care with pneumonia. Patients will be randomly allocated to one of the options in each of these four areas.
A randomised, multi-factorial, adaptive platform clinical trial that will investigate the best treatment for patients with Staphylococcus aureus bloodstream infections. The Trial will simultaneously investigate the best options in multiple areas of practice.
The TAME trial is a phase III, multi-centre, randomised, parallel-group, clinical trial in resuscitated cardiac arrest patients admitted to the intensive care unit to determine whether targeted therapeutic mild hypercapnia (TTMH) improves neurological outcome at 6 months compared to standard care (targeted normocapnia) (TN).
The TTM2 trial is investigating whether targeted temperature management (TTM) to 33°C improves survival and neurological outcome at 6 months compared to a strategy of targeting normothermia and avoiding fever above 37.7°C.